Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Enlivex Therapeutics Ltd (NQ: ENLV ) 1.640 +0.060 (+3.80%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Enlivex Therapeutics Ltd < Previous 1 2 3 4 5 Next > Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session December 26, 2023 Shares of RayzeBio, Inc. (NASDAQ: RYZB) rose sharply during Tuesday’s session after the company announced that it will be acquired by Bristol Myers Squibb for $62.50 per share in cash in a deal worth... Via Benzinga Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis December 20, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer November 21, 2023 From MediWound Ltd. Via GlobeNewswire Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session December 22, 2023 Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results. Via Benzinga Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results September 11, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire Why Fortinet Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Friday's Mid-Day Session November 03, 2023 Gainers Benson Hill, Inc. (NYSE: BHIL) shares jumped 48.1% to $0.3740. Via Benzinga Enlivex to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 07, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Announces Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data Details Resolution of Acute Respiratory Distress Syndrome (ARDS) from two Phase I/II Trials Evaluating Allocetra in Patients with COVID-19 August 02, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis July 31, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update June 26, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire This Biotech Is Bringing Balance To The Body – How Homeostasis Is Critical To Fighting Everything From Sepsis To Cancer June 16, 2023 Oren Hershkovitz, Ph.D., CEO of Enlivex Therapeutics Ltd. (NASDAQ: ENLV) was recently a guest on Benzinga’s All-Access. Via Benzinga Enlivex to Present at the 2023 Jefferies Healthcare Conference June 06, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy May 31, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy May 08, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy April 19, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Appoints Andrew Singer to its Board of Directors April 17, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials April 14, 2023 Via ACCESSWIRE Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials April 13, 2023 This month, H.C. Wainwright & Co. Via Benzinga Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumors April 12, 2023 Via ACCESSWIRE Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumors April 11, 2023 This month, Enlivex Therapeutics Ltd. Via Benzinga Why Pioneer Natural Resources Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket April 10, 2023 Gainers PLx Pharma Inc. (NASDAQ: PLXP) jumped 149.6% to $0.2623 in pre-market trading after dropping over 13% on Thursday. Via Benzinga Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates April 04, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors April 03, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers March 20, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Receives Clearance From Spanish Agency of Medicines and Medical Devices For Treatment of Patients with Advanced Solid Malignancies in the Ongoing Allocetra Phase I/II Clinical Trial February 23, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS February 15, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors January 25, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire Enlivex Receives Authorizations from French and Belgian Regulatory Agencies To Expand Its Phase II Sepsis Clinical Trial Into France and Belgium January 04, 2023 From Enlivex Therapeutics Ltd Via GlobeNewswire A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial December 07, 2022 Enlivex Therapeutics Ltd. (NASDAQ: ENLV) announced that Israel, Spain and Greece have cleared amendments to the company’s Phase II trial protocol that will allow the study to enroll more patients. Via TheNewswire.com A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial December 07, 2022 By Rachael Green, Benzinga Via News Direct < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.